Emerging and novel imaging biomarkers in drug-induced interstitial lung disease

Hot topics
Chairs: P. Camus (Dijon, France), N. Chaudhuri (Manchester (Greater Manchester), United Kingdom)
Aims: (i) To explore the current evidence regarding drug-induced lung toxicity, thereby highlighting its growing impact; (ii) to describe the in vivo models that are being used to elucidate the cell and extracellular matrix changes that underlie drug-induced interstitial lung disease (DIILD) and to identify imaging biomarkers for the detection and quantification of DIILD; (iii) to describe the new imaging techniques for assessing interstitial lung disease and their potential usefulness in DIILD; and (iv) to describe the potential clinical uses of molecular probes for detecting, staging and quantifying fibrosis and fibrogenesis.
Drug-induced interstitial lung disease: known knowns and known unknowns
E. Bendstrup (Vejle, Denmark)
WebcastSlide presentation
WebcastSlide presentation
MRI and CT imaging of in vivo models of drug-induced interstitial lung diseases.
I. Mahmutovic Persson (Lund, Sweden)
WebcastSlide presentation
WebcastSlide presentation
Use of MRI for functional and structural assessment of interstitial lung disease
J. Wild (Sheffield (South Yorkshire), United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Non-invasive molecular imaging of pulmonary fibrosis
S. Montesi (Boston, United States of America)
WebcastSlide presentation
WebcastSlide presentation